InfuSystem Issues Strong 2021 Guidance

Posted on December 15, 2020 by Aaron Warwick

This morning InfuSystem (INFU), a company written about extensively by Breakout Investor, Aaron Warwick (see his most recent INFU article here), announced strong 2021 guidance that outpaced analyst expectations. The company guided for the following in 2021: Revenues of $107 million – $110 million (analysts estimated $106M); Adjusted EBITDA of $29 million – $30 million; Operating Cash Flow of $21 million – $23 million. INFU CEO Rich DiIorio noted: “We are estimating another record year for the Company with solid double-digit growth in net revenue and Adjusted EBITDA driven by strong growth” in their existing business and “successfully executing on a new cross-selling initiative to capitalize on our 2,100 sites of care in Oncology.” Shares closed yesterday at $17.05, up 20%+ since INFU’s most recent earnings release.

Disclosure: I am long INFU and may buy or sell shares at any time.

0 0 votes
Article Rating
Notify of
Inline Feedbacks
View all comments
Would love your thoughts, please comment.x